Send us Fan Mail

 NOT LEGAL ADVICE 

For decades, cannabis research in the U.S. was stifled by Schedule I restrictions, requiring high-security vaults, mountains of paperwork, and extremely limited supply chains. With Executive Order 14370, the landscape has shifted. Marijuana is moving to Schedule III, and the rules of the game have officially changed.

In this episode of KLF Deep Dive, attorney-pharmacist Darshan Kulkarni breaks down the practical impact of this reclassification for clinical trial sponsors. We move beyond the headlines to discuss the "pharmacy-style" compliance now required and the hidden pitfalls of using non-pharmacist staff at trial sites.

Key Topics Covered:

• The Security Shift: Why you can ditch the steel vaults, but why your new "pharmacy" status brings a different set of DEA headaches.
• Supply Chain Normalization: Moving away from the "one-plant" monopoly toward a traditional pharma infrastructure.
• The Real-World Evidence (RWE) Invitation: How the FDA is encouraging the use of patient records and "real-world stories" to prove efficacy.
• The Compliance Trap: Why vetting your trial sites’ staffing—specifically the use of CRNAs vs. Pharmacists—is now a top-tier regulatory risk.
• Targeting Federal Grants: Why studies focusing on veterans and the elderly are currently "first in line" for federal support.

The Bottom Line: The federal government has moved from stopping research to starting it. But as a sponsor, your site list just got bigger—and so did your responsibility to ensure they aren't just pretending to be compliant.

Support the show: www.kulkarnilawfirm.com

Support the show

www.kulkarnilawfirm.com